Published in AIDS Weekly, April 21st, 1997
GEM 91 is a genetic antisense drug designed to attack the HIV genome. The analysis revealed a substantial decrease in cellular viremia levels of up to 1.3 logs (90 percent reduction) in HIV positive-patients treated with GEM 91 after eight days (a log is a 10-fold change). The company also reported it is conducting a Phase II confirmatory clinical study of GEM 91 at multiple clinical centers in the US and Puerto Rico in order to confirm these results.
The unblinded data were collected on 22 HIV...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.